Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Takotsubo Registry

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
L'enllaç es desa al porta-retalls
EstatReclutament
Patrocinadors
Cedars-Sinai Medical Center

Paraules clau

Resum

The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.

Descripció

Registry outreach will begin with an informational and inspirational website and will utilize social media and patient-driven activism through Facebook, blogs and Twitter modalities that have demonstrated efficiencies in other patient-centered research efforts. Subjects will upload specific clinical materials into Cedar-Sinai's web-enabled cloud storage and which will be screened by trained Smidt Heart Institute physicians. The Registry utilizes on-line, e-consent and enrollment connected to a REDCap database that will allow efficient data input for analysis. All potential subjects who have been diagnosed with Takotsubo or have been informed by their physician that they meet diagnosis criteria, will need to provide information for review that includes: hospitalization records, from the time of Takotsubo event, with laboratory data (particularly -- troponin level), ECG and CTA. Registrants will be asked to respond to annual update surveys.

The goal is to accurately understand the prevalence, recurrence and prospective status of the Takotsubo, to determine which individuals are at risk of reoccurrence or subsequent adverse event and to determine potential treatment targets to develop therapeutic strategies

Primary:

- To establish a large USA-based database for patients with Takotsubo with a convenient and easy to use on-line patient-advocate registry using digital media marketing, Box cloud data access and storage, accurate case adjudication, and automated follow-up.

- Participants will also be offered the option of participating in the Takotsubo Proteomic Registry by providing remote ambulatory Mitra blood samples.

Secondary:

• To establish a clinical trial platform for patient-centered point-of-care trials to improve diagnostics, clinical care and outcomes.

Dates

Darrera verificació: 03/31/2019
Primer enviat: 03/05/2019
Inscripció estimada enviada: 04/07/2019
Publicat per primera vegada: 04/09/2019
Última actualització enviada: 04/28/2019
Publicació de l'última actualització: 04/30/2019
Data d'inici de l'estudi real: 01/31/2019
Data estimada de finalització primària: 01/31/2029
Data estimada de finalització de l’estudi: 01/31/2029

Condició o malaltia

Takotsubo Cardiomyopathy

Fase

-

Criteris d'elegibilitat

Edats elegibles per estudiar 18 Years Per a 18 Years
Sexes elegibles per estudiarAll
Mètode de mostreigProbability Sample
Accepta voluntaris saludablesNo
Criteris

Inclusion Criteria:

- Have received a diagnosis of Takotsubo from their physician and consent to enroll

- Submit full medical records needed for Takotsubo adjudication

Exclusion Criteria:

- Younger than 18 years

- Unable to provide informed consent

- Unable to provide the necessary documentation needed for screening purposes

Resultat

Mesures de resultats primaris

1. Number of participants with Prevalence of the Takotsubo [Baseline, Annual follow-up up to 30years]

Prevalence of the Takotsubo will be measured annually. Change from baseline will be assessed.

2. Number of participants with Recurrence the Takotsubo [Baseline, Annual follow-up up to 30years]

Recurrence the Takotsubo will be measured annually. Change from baseline will be assessed.

3. Annual update surveys will collect data on patient's prospective health status following Takotsubo event [Baseline, Annual follow-up up to 30years]

Prospective statusof the Takotsubo will be measured annually. Change from baseline will be assessed.

4. Risk factors affecting which patients, having had one Takotsubo event, will more likely experience a Takotsubo reoccurrence or related subsequent adverse event [Baseline, Annual follow-up up to 30years]

Risk factors for reoccurrence or subsequent adverse event will be collected annually.

Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge